

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	13034340
	Filing Date	2011-02-24
	First Named Inventor	ALAN H. AUERBACH
	Art Unit	1629
	Examiner Name	San Ming R. Hui
	Attorney Docket Number	CGR5001USCNT1

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		13034340
Filing Date		2011-02-24
First Named Inventor	ALAN H. AUERBACH	
Art Unit	1629	
Examiner Name	San Ming R. Hui	
Attorney Docket Number	CGR5001USCNT1	

1	ASCO CANCER FOUNDATION, Poster Session F: Hormone Refractory, ASCO, 2005, -, -	<input type="checkbox"/>
2	BRUNO ET AL, Targeting cytochrome P450 enzymes: A new approach in anti-cancer drug development, Elsevier, 2007, pages 5047-5060, vol. 15	<input type="checkbox"/>
3	CANNELL, 100th Annual Meeting of the American Association for Cancer Research, Los Angeles, CA, USA;, http://oncology.thelancet.com, 2007, pp 471, Volume 8	<input type="checkbox"/>
4	Collins, et al. "A Systematic Review of the effectiveness of Docetaxel and Mitoxantrone for the Treatment of Metastatic Hormone-Refractory Prostate Cancer", British J. of Cancer, 95, pp 457-462 (2006)	<input type="checkbox"/>
5	COUGAR BIOTECHNOLOGY, Cougar Biotechnology Announces Initiation of Phase I/II Trial for CB7630 (Arbiterone Acetate), Cougar Biotechnology, 12-14-2004, -, -	<input type="checkbox"/>
6	COUGAR BIOTECHNOLOGY, Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Cougar Biotechnology, 10-2007, -, -	<input type="checkbox"/>
7	COUGAR BIOTECHNOLOGY, Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference, Drugs.com, 7-2007, -, -	<input type="checkbox"/>
8	COUGAR BIOTECHNOLOGY, Cougar Biotechnology announces presentation of positive phase I and phase II data at ASCO Prostate Cancer Symposium, Cougar Biotechnology, 02-23-2007, -, -	<input type="checkbox"/>
9	COUGAR BIOTECHNOLOGY, Cougar Biotechnology presents CB7630 Phase I clinical data at the 2005 Prostate Cancer Symposium, AllBusiness, 2005, -, -	<input type="checkbox"/>
10	COUGAR BIOTECHNOLOGY, Cougar Biotechnology presents positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session, Cougar Biotechnology, 04-17-2007, -, -	<input type="checkbox"/>
11	COUGAR BIOTECHNOLOGY, Cougar Technology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting, The Free Library, 06-04-2007, -, -	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	13034340
Filing Date	2011-02-24
First Named Inventor	ALAN H. AUERBACH
Art Unit	1629
Examiner Name	San Ming R. Hui
Attorney Docket Number	CGR5001USCNT1

12	DE BONO ET AL, Inhibition of CYP450c17 by abiraterone administered once daily to castrate patients with prostate cancer resistant to LHRH analogues, anti-androgens and steroid therapy is well tolerated..., The institute of Cancer Research, 2007, -, -	<input type="checkbox"/>
13	DE COSTER, ET AL., Effects of High-Dose Ketoconazole and Dexamethason on ACTH-Stimulated Adrenal Steriodogenesis in Orchiectomized Prostatic Cancer Patients, Acta Endocrinologica (Copenh), 1987, pp 265-271, Volume 115	<input type="checkbox"/>
14	DUC ET AL, In Vitro and in vivo models for the evaluation of potent inhibitors of male rat 17 -hydroxylase/C-lyase, Pergamon, 2003, pages 537-542, vol. 84	<input type="checkbox"/>
15	ENDOCRINOLOGY, Inhibition of Androgen Synthesis in Human Testicular and Prostatic Microsomes and in Male Rats by Novel Steroidal Compounds, Endocrinology, 1999, pages 2891-2897, vol. 140 No. 6	<input type="checkbox"/>
16	FOSSA, ET AL., Weekly Docetaxel and Prednisone Versus Prednisolone Alone in Androgen-Independent Prostate Cancer: A Randomized Phase II Study, European Urology, 2007, pp 1691-1699, Volume 52	<input type="checkbox"/>
17	GERBER, ET AL., Prostate Specific Antigen for Assessing Response to Ketoconazole and Prednisone in Patients with Hormone Refractory Metastatic Prostate Cancer, The Journal of Urology, 1990, pp 1177-1179, Volume 144, Number 5	<input type="checkbox"/>
18	HAKKI ET AL, CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets, Elsevier, 2006, pages 27-52, vol. 11	<input type="checkbox"/>
19	HARRIS, ET AL., Low Dose Ketoconazole with Replacement Doses of Hydrocortisone in Patients with Progressive Androgen Independent Prostate Cancer, The Journal of Urology, 2002, pp 542-545, Volume 168	<input type="checkbox"/>
20	MOREIRA ET AL, Synthesis and evaluation of novel 17-indazole androstene derivatives designed as CYP17 inhibitors, Elsevier, 2007, pages 939-948, vol. 72	<input type="checkbox"/>
21	NEWELL ET AL, The Cancer Research UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies, Elsevier, 2004, pages 899-906, vol. 40	<input type="checkbox"/>
22	PETRYLAK, ET AL., Future Directions in the Treatment of Androgen-Independent Prostate Cancer, Urology, 2005, pp 8-13, Volume 65, Supplement 6A	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	13034340
	Filing Date	2011-02-24
	First Named Inventor	ALAN H. AUERBACH
	Art Unit	1629
	Examiner Name	San Ming R. Hui
	Attorney Docket Number	CGR5001USCNT1

23	SCHOLZ, ET AL., Long-Term Outcome for Men with Androgen Independent Prostate Cancer Treated with Ketoconazole and Hydrocortisone, The Journal of Urology, 2005, pp 1947-1952, Volume 173	<input type="checkbox"/>
24	SMALL ET AL, The Case for Socondary Hormaonal Therapies in the Chemotherapy Age, The Journal of Urology, 2006, pages S66 - S71, vol. 176	<input type="checkbox"/>
25	WIKIPEDIA, Corticosteriod, undated, website	<input type="checkbox"/>
26		<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.